Genotype of CDC73 germline mutation determines risk of parathyroid cancer

in Endocrine-Related Cancer
View More View Less
  • 1 Division of Endocrinology, Department of Medicine, Penn State University College of Medicine, Hershey, Pennsylvania, USA
  • 2 Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA
  • 3 Thoracic Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA

Correspondence should be addressed to Y Li or H Chen or W F Simond: yulongli@pennstatehealth.psu.edu or haobin.chen@nih.gov or bills@niddk.nih.gov
Restricted access

Mutation of the CDC73 gene, which encodes parafibromin, has been linked with parathyroid cancer. However, no correlation between genotypes of germline CDC73 mutations and the risk of parathyroid cancer has been known. In this study, subjects with germline CDC73 mutations were identified from the participants of two clinical protocols at National Institutes of Health (Discovery Cohort) and from the literature (Validation Cohort). The relative risk of developing parathyroid cancer was analyzed as a function of CDC73 genotype, and the impact of representative mutations on structure of parafibromin was compared between genotype groups. A total of 419 subjects, 68 in Discovery Cohort and 351 in Validation Cohort, were included. In both cohorts, percentages of CDC73 germline mutations that predicted significant conformational disruption or loss of expression of parafibromin (referred as ‘high-impact mutations’) were significantly higher among the subjects with parathyroid cancers compared to all other subjects. The Kaplan–Meier analysis showed that high-impact mutations were associated with a 6.6-fold higher risk of parathyroid carcinoma compared to low-impact mutations, despite a similar risk of developing primary hyperparathyroidism between two groups. Disruption of the C-terminal domain (CTD) of parafibromin is directly involved in predisposition to parathyroid carcinoma, since only the mutations impacting this domain were associated with an increased risk of parathyroid carcinoma. Structural analysis revealed that a conserved surface structure in the CTD is universally disrupted by the mutations affecting this domain. In conclusion, high-impact germline CDC73 mutations were found to increase risk of parathyroid carcinoma by disrupting the CTD of parafibromin.

Supplementary Materials

    • Supplementary Figure 1. Comparison of clinical features in the subjects with parathyroid classic adenomas, atypical parathyroid adenomas, or parathyroid carcinomas. The dot plots show difference between the marked groups on a) age at the diagnosis of hyperparathyroidism; b) parathyroid tumor size; c) serum calcium levels; and d) serum PTH levels.
    • Supplementary Figure 2. Kaplan-Meier plots of event-free survival of parathyroid carcinoma (left) and hyperparathyroidism (right) in several subsets of the subjects grouped by high-or low-impact germline mutationsof the CDC73 gene: (a,b) Subjects with CDC73germline mutations that were confirmed by DNA sequencing; (c,d) subjects who were index cases; and (e,f) subjects after atypical parathyroid adenomas were excluded.
    • Supplementary Figure 3. Kaplan-Meier plots of event-free survival of parathyroid carcinoma (a) and hyperparathyroidism (b) in the subjects grouped by mutation types of high-impact mutations in comparison to the subjects with low-impact mutations.
    • Supplementary Figure 4. Impact of the mutations on expression of parafibromin and binding to CTR9 (a key component of PAF1 complex). a) Various Flag-tagged CDC73 (HRPT2) mutants and WT were transiently expressed in HEK 293 cells and expression of parafibromin was examined by western blot using an anti-Flag antibody at 48 hours after transfection. b) Co-immunoprecipitation of HA-tagged CTR9 and Flag-tagged CDC73 WT/mutants using anti-HA antibody. Rabbit IgG isotype control (Cell Signaling) was used as a negative control for IP (IgG IP). The presence of Flag-tagged CDC73 WT/mutants and HA-tagged CTR9 in the IP eluates were detected by western blot using anti-Flag HRP-conjugated antibody and anti-HA HRP-conjugated antibody, respectively. WT CDC73 was used as a positive control and the c.406A>T (p.136X) mutant, which lacks the central CTR9 binding sequence (aa. 226-413), was used as a negative control. The low-impact mutations are highlighted in light green color and high-impact mutations are in magenta color; the parathyroid carcinoma-associated mutations are underlined. The experiments were performed at least twice.
    • Supplementary Figure 5. Kaplan-Meier plots of event-free survival of parathyroid carcinoma (left) and hyperparathyroidism (right) in several subsets of the subjects grouped by the mutations affecting the NTD only (N), the CTD only (C) or both protein domains (N+C): (a,b) Subjects with sequencing-confirmed CDC73germline mutations; (c,d) subjects who were index cases; and (e,f) subjects after atypical parathyroid adenomas were excluded.
    • Supplementary Table 1. List of the published case reports/case series included in the present study.
    • Supplementary Table 2. Mutation type, genotype group and parathyroid phenotype of all subjects included in the present study.
    • Table S3. The percentages of the low-impact and the high-impact mutations in the subjects who developed jaw disease, kidney disease or uterine disease. The ratio of the above mutations in the subjects who developed the specified disease was compared to the ratio in all the subjects. The significance of the difference was calculated using chi-square or Fisher’s exact test, as appropriate.
    • Table S4. The percentages of the mutations impacting on the NTD only, the CTD only, or both domains in the subjects with jaw disease, kidney disease, or uterine disease. The ratios of the above mutations in the subjects who developed the specified disease were compared to the ratio in all the subjects. The significance of the difference was calculated using chi-square or Fisher’s exact test, as appropriate.

 

      Society for Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 671 671 118
Full Text Views 49 49 7
PDF Downloads 33 33 3
  • Amrich CG, Davis CP, Rogal WP, Shirra MK, Heroux A, Gardner RG, Arndt KM & VanDemark AP 2012 Cdc73 subunit of Paf1 complex contains C-terminal Ras-like domain that promotes association of Paf1 complex with chromatin. Journal of Biological Chemistry 287 1086310875. (https://doi.org/10.1074/jbc.M111.325647)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Bondeson L, Grimelius L, DeLellis RA, Lloyd R, Akerstrom G, Larsson C, Arnold A, Eng C, Shane E & Bilezikian JP 2004 Parathyroid carcinoma. In World Health Organization Classification of Tumors: Pathology & Genetics: Tumors of Endocrine Organs, pp 124127. Eds DeLellis RA, Lloyd RV, Heitz PU & Eng. C Lyon, France: IARC Press.

    • Search Google Scholar
    • Export Citation
  • Carpten JD, Robbins CM, Villablanca A, Forsberg L, Presciuttini S, Bailey-Wilson J, Simonds WF, Gillanders EM, Kennedy AM & Chen JD 2002 HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nature Genetics 32 676680. (https://doi.org/10.1038/ng1048)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Cetani F, Marcocci C, Torregrossa L & Pardi E 2019 Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors. Endocrine-Related Cancer 26 R441R464. (https://doi.org/10.1530/ERC-19-0135)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Chen H, Shi N, Gao Y, Li X, Teng M & Niu L 2012 Crystallographic analysis of the conserved C-terminal domain of transcription factor Cdc73 from Saccharomyces cerevisiae reveals a GTPase-like fold. Acta Crystallographica: Section D, Biological Crystallography 68 953959. (https://doi.org/10.1107/S0907444912017325)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Clarke CN, Katsonis P, Hsu TK, Koire AM, Silva-Figueroa A, Christakis I, Williams MD, Kutahyalioglu M, Kwatampora L & Xi Y, 2019 Comprehensive genomic characterization of parathyroid cancer identifies novel candidate driver mutations and core pathways. Journal of the Endocrine Society 3 544559. (https://doi.org/10.1210/js.2018-00043)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Cui M, Hu Y, Bi Y, Wang W, Wang M, Zhang X, Zhang R, Wang P, Su Z & Gao X, 2019 Preliminary exploration of potential molecular therapeutic targets in recurrent and metastatic parathyroid carcinomas. International Journal of Cancer 144 525532. (https://doi.org/10.1002/ijc.31948)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • DeLellis R, Larsson C, Arnold A, Lloy R, Bilezikian J, Mete O & Eng C 2017 Tumors of the parathyroid glands. In WHO Classification of Tumors of Endocrine Organs, pp 145159. Eds Lloyd R, Osamura R, Kloppel G & Rosai J. Lyon, France: IARC Press.

    • Search Google Scholar
    • Export Citation
  • Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I & Takai SI 1996 The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276 15751579. (https://doi.org/10.1001/jama.1996.03540190047028)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Frank-Raue K, Hoppner W, Frilling A, Kotzerke J, Dralle H, Haase R, Mann K, Seif F, Kirchner R & Rendl J, 1996 Mutations of the RET protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group. Journal of Clinical Endocrinology & Metabolism 81 17801783. (https://doi.org/10.1210/jcem.81.5.8626834)

    • Search Google Scholar
    • Export Citation
  • Gill AJ 2014 Understanding the genetic basis of parathyroid carcinoma. Endocrine Pathology 25 3034. (https://doi.org/10.1007/s12022-013-9294-3)

  • Gill AJ, Lim G, Cheung VKY, Andrici J, Perry-Keene JL, Paik J, Sioson L, Clarkson A, Sheen A, Luxford C, 2019 Parafibromin-deficient (HPT-JT type, CDC73 mutated) parathyroid tumors demonstrate distinctive morphologic features. American Journal of Surgical Pathology 43 3546. (https://doi.org/10.1097/PAS.0000000000001017)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Hahn MA & Marsh DJ 2005 Identification of a functional bipartite nuclear localization signal in the tumor suppressor parafibromin. Oncogene 24 62416248. (https://doi.org/10.1038/sj.onc.1208778)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Hahn MA & Marsh DJ 2007 Nucleolar localization of parafibromin is mediated by three nucleolar localization signals. FEBS Letters 581 50705074. (https://doi.org/10.1016/j.febslet.2007.09.050)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Iwata T, Mizusawa N, Taketani Y, Itakura M & Yoshimoto K 2007 Parafibromin tumor suppressor enhances cell growth in the cells expressing SV40 large T antigen. Oncogene 26 61766183. (https://doi.org/10.1038/sj.onc.1210445)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Jackson MA, Rich TA, Hu MI, Perrier ND & Waguespack SG 1993 CDC73-related disorders. In Gene Reviews (R). Eds Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Ledbetter N, Mefford HC, Smith RJH, Seattle, WA, USA: University of Washington. (available at: https://www.ncbi.nlm.nih.gov/books/NBK3789/)

    • Search Google Scholar
    • Export Citation
  • Krebs LJ, Shattuck TM & Arnold A 2005 HRPT2 mutational analysis of typical sporadic parathyroid adenomas. Journal of Clinical Endocrinology & Metabolism 90 50155017. (https://doi.org/10.1210/jc.2005-0717)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Lee PK, Jarosek SL, Virnig BA, Evasovich M & Tuttle TM 2007 Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer 109 17361741. (https://doi.org/10.1002/cncr.22599)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Li Y & Simonds WF 2016 Endocrine neoplasms in familial syndromes of hyperparathyroidism. Endocrine-Related Cancer 23 R229R247. (https://doi.org/10.1530/ERC-16-0059)

  • Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD, Wahl RA, Lamesch P, Raue F, Conte-Devolx B, 2003 Early malignant progression of hereditary medullary thyroid cancer. New England Journal of Medicine 349 15171525. (https://doi.org/10.1056/NEJMoa012915)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Mosimann C, Hausmann G & Basler K 2006 Parafibromin/Hyrax activates Wnt/Wg target gene transcription by direct association with beta-catenin/Armadillo. Cell 125 327341. (https://doi.org/10.1016/j.cell.2006.01.053)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Mosimann C, Hausmann G & Basler K 2009 The role of Parafibromin/Hyrax as a nuclear Gli/Ci-interacting protein in Hedgehog target gene control. Mechanisms of Development 126 394405. (https://doi.org/10.1016/j.mod.2009.02.002)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Newey PJ, Bowl MR, Cranston T & Thakker RV 2010 2010 cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors. Human Mutation 31 295307. (https://doi.org/10.1002/humu.21188)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Pandya C, Uzilov AV, Bellizzi J, Lau CY, Moe AS, Strahl M, Hamou W, Newman LC, Fink MY & Antipin Y, 2017 Genomic profiling reveals mutational landscape in parathyroid carcinomas. JCI Insight 2 e92061. (https://doi.org/10.1172/jci.insight.92061)

    • PubMed
    • Search Google Scholar
    • Export Citation
  • Panicker LM, Zhang JH, Dagur PK, Gastinger MJ & Simonds WF 2010 Defective nucleolar localization and dominant interfering properties of a parafibromin L95P missense mutant causing the hyperparathyroidism-jaw tumor syndrome. Endocrine-Related Cancer 17 513524. (https://doi.org/10.1677/ERC-09-0272)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Pazienza V, la Torre A, Baorda F, Alfarano M, Chetta M, Muscarella LA, Battista C, Copetti M, Kotzot D & Kapelari K 2013 Identification and functional characterization of three NoLS (nucleolar localisation signals) mutations of the CDC73 gene. PLoS One 8 e82292. (https://doi.org/10.1371/journal.pone.0082292)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Rodrigo JP, Hernandez-Prera JC, Randolph GW, Zafereo ME, Hartl DM, Silver CE, Suarez C, Owen RP, Bradford CR & Makitie AA, 2020 Parathyroid cancer: an update. Cancer Treatment Reviews 86 102012. (https://doi.org/10.1016/j.ctrv.2020.102012)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Shattuck TM, Valimaki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K, Robbins CM & Carpten JD, 2003 Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. New England Journal of Medicine 349 17221729. (https://doi.org/10.1056/NEJMoa031237)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Sun W, Kuang XL, Liu YP, Tian LF, Yan XX & Xu W 2017 Crystal structure of the N-terminal domain of human CDC73 and its implications for the hyperparathyroidism-jaw tumor (HPT-JT) syndrome. Scientific Reports 7 15638. (https://doi.org/10.1038/s41598-017-15715-9)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Wei CH & Harari A 2012 Parathyroid carcinoma: update and guidelines for management. Current Treatment Options in Oncology 13 1123. (https://doi.org/10.1007/s11864-011-0171-3)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Wei Z, Sun B, Wang ZP, He JW, Fu WZ, Fan YB & Zhang ZL 2018 Whole-exome sequencing identifies novel recurrent somatic mutations in sporadic parathyroid adenomas. Endocrinology 159 30613068. (https://doi.org/10.1210/en.2018-00246)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Wimley WC & White SH 1996 Experimentally determined hydrophobicity scale for proteins at membrane interfaces. Nature Structural Biology 3 842848. (https://doi.org/10.1038/nsb1096-842)

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • Yang J, Yan R, Roy A, Xu D, Poisson J & Zhang Y 2015 The I-TASSER Suite: protein structure and function prediction. Nature Methods 12 78. (https://doi.org/10.1038/nmeth.3213)

  • Yart A, Gstaiger M, Wirbelauer C, Pecnik M, Anastasiou D, Hess D & Krek W 2005 The HRPT2 tumor suppressor gene product parafibromin associates with human PAF1 and RNA polymerase II. Molecular & Cellular Biology 25 50525060. (https://doi.org/10.1128/MCB.25.12.5052-5060.2005)

    • Crossref
    • Search Google Scholar
    • Export Citation
  • Yu W, McPherson JR, Stevenson M, van Eijk R, Heng HL, Newey P, Gan A, Ruano D, Huang D & Poon SL, 2015 Whole-exome sequencing studies of parathyroid carcinomas reveal novel PRUNE2 mutations, distinctive mutational spectra related to APOBEC-catalyzed DNA mutagenesis and mutational enrichment in kinases associated with cell migration and invasion. Journal of Clinical Endocrinology & Metabolism 100 E360E364. (doi:10.1210/jc.2014-3238)

    • Crossref
    • Search Google Scholar
    • Export Citation